Merck begins tender offer to buy Terns Pharmaceuticals

Merck begins tender offer to buy Terns Pharmaceuticals
Terns Pharma shares surge on $6.7B Merck buyout deal at $53 per share
Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT
4 stocks to watch on Monday: MRK, DPZ, GILD, HON
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more - CNBC
📅IT’S A BIG WEEK OF EARNINGS! 📈 $GOOGL $AMZN $AMD $PLTR $QCOM $ARM $SMCI $RDDT $RBLX $SNAP $PYPL $AFRM $UBER $DIS $PEP $CMG $TSN $LLY $NVO $PFE $MRK $COP $SHEL $B WILL DELIVER RESULTS! 💰MAKE SMARTER INVESTMENT DECISIONS WITH ‘PRO PICKS AI’: 🎁GET 50% OFF ALL PRO PLANS FOR https://t.co/hCLP39WM0n
298.84BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US58933Y1055
CUSIP
589339209
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
16.60
PEG Ratio
3.68
Book Value
21.26
Dividend Share
3.24
Dividend Yield
2.68%
Earnings Share
7.28
Wall Street Target Price
128.59
EPS Estimate Current Year
5.12
EPS Estimate Next Year
9.74
EPS Estimate Current Quarter
2.0105
EPS Estimate Next Quarter
-1.3978
Most Recent Quarter
-
Revenue TTM
65,010,999,296
Gross Profit TTM
50,196,000,768
EBITDA
29,105,000,448
Profit Margin
28.08%
Return On Assets TTM
12.04%
Return On Equity TTM
36.88%
Revenue Per Share TTM
25.984
Qtly Revenue Growth YOY
5.00%
Diluted Eps TTM
7.28
Qtly Earnings Growth YOY
-19.30%
Trailing PE
16.60
Forward PE
23
Price Sales TTM
4.596
Price Book MRQ
5.6807
Enterprise Value Revenue
5
Enterprise Value EBITDA
11
942.25
1.68%207.70
0.49%241.78
0.34%49.98
0.26%343.20
0.19%154.88
0.00%406.44
-2.36%200.81
-1.01%400.00
-0.99%151.96
-0.61%Curated watchlists where MRK is featured.